USFDA sends CRL to Merck’s sBLA regarding KEYTRUDA
Merck has announced that the US Food and Drug Administration (FDA) has sent a Complete Response Letter (CRL) regarding Merck’s supplemental Biologics License Application (sBLA) for the approval
Vividion Therapeutics has announced plans to broaden its capabilities with the establishment of a new research and development (R&D) centre and corporate headquarters at San Diego in California, US.
US-based global biotechnology company Dyadic International has announced the expansion of its partnership with South Korea-based global research biopharmaceutical company Medytox to co-develop C1 manufactured Covid-19 vaccines. Dyadic’s